Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Риск развития артериальной гипертонии у пациентов с онкологическими заболеваниями на фоне противоопухолевого лечения
Риск развития артериальной гипертонии у пациентов с онкологическими заболеваниями на фоне противоопухолевого лечения
Чазова И.Е., Ощепкова Е.В., Кириллова М.Ю., Стенина М.Б. Риск развития артериальной гипертонии у пациентов с онкологическими заболеваниями на фоне противоопухолевого лечения. Consilium Medicum. 2016; 18 (1): 16–20. DOI: 10.26442/2075-1753_2016.1.16-20
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В последние годы в медицине создано новое направление, объединившее усилия кардиологов и онкологов, – кардиоонкология, задачами которой являются разработка и оптимизация алгоритмов совместного ведения онкологических больных с целью минимизации кардиотоксического эффекта противоопухолевого лечения, что позволит улучшить прогноз и увеличить продолжительность их жизни. Известно, что химиотерапевтические препараты направленного действия могут оказывать кардио- и вазотоксическое действие, способствуя развитию и обострению имеющихся сердечно-сосудистых заболеваний. Артериальная гипертония (АГ) является одним из осложнений противоопухолевой терапии злокачественных онкологических заболеваний (ОЗ) и наиболее часто возникает при назначении ингибиторов рецептора эпидермального фактора роста. Истинную частоту «впервые возникшей» АГ у этой категории больных определить довольно сложно, и она варьируется в значительных пределах в зависимости от типа, дозы, временного периода проведения химиотерапии. Обследование и лечение пациентов с ОЗ, у которых развилась АГ на фоне химиотерапии, проводится согласно общепринятым рекомендациям, однако имеются особенности при назначении разных классов антигипертензивных препаратов.
Ключевые слова: кардиоонкология, артериальная гипертония, кардиотоксичность, антигипертензивная терапия при онкологических заболеваниях, химиотерапия.
Key words: cardio-oncology, arterial hypertension, cardiotoxicity, antihypertensive therapy in cancer patients, chemotherapy.
Ключевые слова: кардиоонкология, артериальная гипертония, кардиотоксичность, антигипертензивная терапия при онкологических заболеваниях, химиотерапия.
________________________________________________
Key words: cardio-oncology, arterial hypertension, cardiotoxicity, antihypertensive therapy in cancer patients, chemotherapy.
Полный текст
Список литературы
1. Piccirillo JF, Tierney RM, Costas I et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291 (20): 2441–7.
2. Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. Распространенность факторов риска сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014; 54: 4–12. / Chazova I.E., Zhernakova Iu.V., Oshchepkova E.V. i dr. Rasprostranennost' faktorov riska serdechno-sosudistykh zabolevanii v rossiiskoi populiatsii bol'nykh arterial'noi gipertoniei. Kardiologiia. 2014; 54: 4–12. [in Russian]
3. Guo X. Association between pre-hypertension and cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Curr Hypertens Rep 2013; 15: 703–16.
4. Hamnvik OP, Choueiri TK, Turchin A et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer 2015; 121 (2): 311–9.
5. Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370:2011–9. Brookes L. National Health and Nutrition Examination Survey (NHANES) data on hypertension. In: American Society of Hypertension 18th Annual Scientific Session. 2003.
6. Caro J, Morales E, Gutierrez E et al. Malignant hypertension in patients treated with vascular endothelial growth factor inhibitors. J Clin Hypertens (Greenwich) 2013; 15: 215–6.
7. Rini BI, Cohen DP, Lu DR et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103: 763–73.
8. Wijermans PW, Lubbert M, Verhoef G et al. An epigenetic approach to the treatment of advanced MDS; the experience withthe DNA demethylating agent 5-aza-2-deoxycytidine (decitabine) in 177 patients. Ann Hematol 2005; 84 (Suppl. 1): 9–17.
9. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 2004; 7: 193–201.
10. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427–34.
11. Oza FM, Cook AD, Pfisterer J et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomized trial. Lancet Oncol 2015; 16: 928–36.
12. Chu TF, Rupnick MA. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011–9.
13. Funakoshi T, Latif A, Galsky MD. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis. J Hum Hypertens 2013; 27: 601–11.
14. Veronese et al. Mechanisms of hypertension associated with BAY43-9006. J Clin Oncol 2006; 24: 1363–9.
15. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009; 6 (8): 465–77.
16. Mourad JJ, Des Guetz G, Debbabi H et al. Blood pressure rise following angiogenesis inhibition bybevacizumab. A crucial role for microcirculation. Ann Oncol 2008; 19: 927–34.
17. Ciuffetti G, Schillaci G, Innocente S et al. Capillary rarefaction and abnormal cardiovascular reactivity in hypertension. J Hypertens 2003; 21: 2297–303.
18. Randall LM, Monk BJ. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol 2010; 117 (3): 497–504.
19. Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY43-9006. J Clin Oncol 2006; 24: 1363–9.
20. Bair SM, Choueiri TK, Moslehi J. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc Med 2013.
21. Диагностика и лечение артериальной гипертонии. Клинические рекомендации. Кардиологический вестн. 2015; 1: 3–30. / Diagnostika i lechenie arterial'noi gipertonii. Klinicheskie rekomendatsii. Kardiologicheskii vestn. 2015; 1: 3–30. [in Russian]
22. Maitland ML, Bakris GL, Black HR et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102: 596–604.
23. Рогоза А.Н., Гориева Ш.Б., Мордвинова Е.В. Возможности тонометров высокого класса точности в обеспечении дистанционного самоконтроля артериального давления. РМЖ. Кардиология. Эндокринология. 2014; 23: 1707–13. / Rogoza A.N., Gorieva Sh.B., Mordvinova E.V. Vozmozhnosti tonometrov vysokogo klassa tochnosti v obespechenii distantsionnogo samokontrolia arterial'nogo davleniia. RMZh. Kardiologiia. Endokrinologiia. 2014; 23: 1707–13. [in Russian]
24. Romano S, Fratini S, Ricevuto E et al. Serial measurements of NT-pro BNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. Br J Cancer 2011; 105: 1663–8.
25. Cardinale D, Sandri MT, Martinoni A et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000; 36: 517–22.
26. Plana JC Et al. Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014; 27: 911–39.
27. Maitland ML, Kasza KE, Karrison TG et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 2009; 15 (19): 6250–7.
28. Jain M, Townsend RR. Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep 2007; 9: 320–8.
29. Kim JJ, Vaziri SA, Rini BI. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 2012; 118 (7): 1946–54.
30. Rini BI, Cohen DP, Lu DR et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103: 763–73.
31. Rini BI, Schiller JH, Fruehauf JP. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011; 17: 3841–9.
32. Copur MS, Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer 2011; 10: 151–6.
33. Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation 2011; 124: 1687–91.
34. Grossman E, Messerli FH. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med 2012; 125: 14–22.
35. Izzedine H, Ederhy S, Goldwasser F et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009; 20: 807–15.
36. Graves SW, Eder JP, Schryber SM et al. Endogenous digoxin-like immunoreactive factor and digitalis-like factor associated with the hypertension of patients receiving multiple alkylating agents as part of autologous bone marrow transplantation. Clin Sci (London) 1989; 77: 501–7.
37. Berliner S, Rahima M, Sidi Y et al. Acute coronary events following cisplatin-based chemotherapy. Cancer Invest 1990; 8: 583–6.
38. Cifkova R, Hallen H. Cyclosporin-induced hypertension. J Hypertens 2001; 19: 2283–5.
39. Rodicio JL. Calcium antagonists and renal protection from cyclosporine nephrotoxicity: long-term trial in renal transplantation patients. J Cardiovasc Pharmacol 2000; 35: S7–11.
40. Curtis JJ. Captopril-induced fall in glomerular filtration rate in cyclosporine-treated hypertensive patients. J Am Soc Nephrol 1993; 3: 1570–4.
41. Schmidt A. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serumuric acid levels and potassium homeostasis in hypertensive renal trans-plant recipients treated with CsA. Nephrol Dial Transplant 2001; 16: 1034–7.
42. Grossman EMF. Management of drug-induced and iatrogenic hypertension. In: Hypertension primer. 3rd ed. Dallas, TX: Lippincott Williams& Wilkins, 2003; p. 516–9.
43. Powe DG, Entschladen F. Targeted therapies: Using beta-blockers to inhibit breast cancer progression. Nature Rev Clin Oncol 2011; 8: 511–2.
44. Powe DG, Voss MJ, Zanker KS et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010; 1: 628–38.
45. Gulati G, Heck SL, Hoffman P et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): primary results of a randomized, 2 × 2 factorial, placebo-controlled, double-blind clinical trial. American Heart Association 2015 Scientific Sessions; November 11, 2015; Orlando, FL. Abstract 2015-LBCT-20236-AHA.
46. TITAN (Multidisciplinary Team IntervenTion in CArdio-Oncology). https://clinicaltrials.gov/ct2/show/NCT01621659?term=cardio-oncology&rank=1
47. Чазова И.Е., Ощепкова Е.В., Канторова А.Ю. Коморбидность сердечно-сосудистых и онкологических заболеваний: проблемы диагностики кардиотоксических эффектов химио- и лучевой терапии. Терапевт. арх. 2015; 9 (87): 4–11. / Chazova I.E., Oshchepkova E.V., Kantorova A.Iu. Komorbidnost' serdechno-sosudistykh i onkologicheskikh zabolevanii: problemy diagnostiki kardiotoksicheskikh effektov khimio- i luchevoi terapii. Terapevt. arkh. 2015; 9 (87): 4–11. [in Russian]
48. Чазова И.Е., Ощепкова Е.В., Кириллова М.Ю., Шарипова Г.Х. Сердечно-сосудистые и онкологические заболевания: поиск решений новых проблем. Системные гипертензии. 2015; 12 (2): 6–7. / Chazova I.E., Oschepkova E.V., Kirillova M.Yu., Sharipova G.Ch. Cardioncology: management of arterial hypertension in patients with cancer on chemotherapy. Systemic Hypertension. 2015; 12 (2): 6–7. [in Russian]
49. Chazova IE, Ovchinnikov AG, Ageev FT. Early diagnostics and prevention of antracycline-induced cardiomyopathy: a role of cardiologist. OnCO Rev 2015; 5 (4 A): 169–76.
2. Chazova I.E., Zhernakova Iu.V., Oshchepkova E.V. i dr. Rasprostranennost' faktorov riska serdechno-sosudistykh zabolevanii v rossiiskoi populiatsii bol'nykh arterial'noi gipertoniei. Kardiologiia. 2014; 54: 4–12. [in Russian]
3. Guo X. Association between pre-hypertension and cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Curr Hypertens Rep 2013; 15: 703–16.
4. Hamnvik OP, Choueiri TK, Turchin A et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer 2015; 121 (2): 311–9.
5. Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370:2011–9. Brookes L. National Health and Nutrition Examination Survey (NHANES) data on hypertension. In: American Society of Hypertension 18th Annual Scientific Session. 2003.
6. Caro J, Morales E, Gutierrez E et al. Malignant hypertension in patients treated with vascular endothelial growth factor inhibitors. J Clin Hypertens (Greenwich) 2013; 15: 215–6.
7. Rini BI, Cohen DP, Lu DR et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103: 763–73.
8. Wijermans PW, Lubbert M, Verhoef G et al. An epigenetic approach to the treatment of advanced MDS; the experience withthe DNA demethylating agent 5-aza-2-deoxycytidine (decitabine) in 177 patients. Ann Hematol 2005; 84 (Suppl. 1): 9–17.
9. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 2004; 7: 193–201.
10. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427–34.
11. Oza FM, Cook AD, Pfisterer J et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomized trial. Lancet Oncol 2015; 16: 928–36.
12. Chu TF, Rupnick MA. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011–9.
13. Funakoshi T, Latif A, Galsky MD. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis. J Hum Hypertens 2013; 27: 601–11.
14. Veronese et al. Mechanisms of hypertension associated with BAY43-9006. J Clin Oncol 2006; 24: 1363–9.
15. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009; 6 (8): 465–77.
16. Mourad JJ, Des Guetz G, Debbabi H et al. Blood pressure rise following angiogenesis inhibition bybevacizumab. A crucial role for microcirculation. Ann Oncol 2008; 19: 927–34.
17. Ciuffetti G, Schillaci G, Innocente S et al. Capillary rarefaction and abnormal cardiovascular reactivity in hypertension. J Hypertens 2003; 21: 2297–303.
18. Randall LM, Monk BJ. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol 2010; 117 (3): 497–504.
19. Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY43-9006. J Clin Oncol 2006; 24: 1363–9.
20. Bair SM, Choueiri TK, Moslehi J. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc Med 2013.
21. Diagnostika i lechenie arterial'noi gipertonii. Klinicheskie rekomendatsii. Kardiologicheskii vestn. 2015; 1: 3–30. [in Russian]
22. Maitland ML, Bakris GL, Black HR et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102: 596–604.
23. Rogoza A.N., Gorieva Sh.B., Mordvinova E.V. Vozmozhnosti tonometrov vysokogo klassa tochnosti v obespechenii distantsionnogo samokontrolia arterial'nogo davleniia. RMZh. Kardiologiia. Endokrinologiia. 2014; 23: 1707–13. [in Russian]
24. Romano S, Fratini S, Ricevuto E et al. Serial measurements of NT-pro BNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. Br J Cancer 2011; 105: 1663–8.
25. Cardinale D, Sandri MT, Martinoni A et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000; 36: 517–22.
26. Plana JC Et al. Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014; 27: 911–39.
27. Maitland ML, Kasza KE, Karrison TG et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 2009; 15 (19): 6250–7.
28. Jain M, Townsend RR. Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep 2007; 9: 320–8.
29. Kim JJ, Vaziri SA, Rini BI. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 2012; 118 (7): 1946–54.
30. Rini BI, Cohen DP, Lu DR et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103: 763–73.
31. Rini BI, Schiller JH, Fruehauf JP. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011; 17: 3841–9.
32. Copur MS, Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer 2011; 10: 151–6.
33. Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation 2011; 124: 1687–91.
34. Grossman E, Messerli FH. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med 2012; 125: 14–22.
35. Izzedine H, Ederhy S, Goldwasser F et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009; 20: 807–15.
36. Graves SW, Eder JP, Schryber SM et al. Endogenous digoxin-like immunoreactive factor and digitalis-like factor associated with the hypertension of patients receiving multiple alkylating agents as part of autologous bone marrow transplantation. Clin Sci (London) 1989; 77: 501–7.
37. Berliner S, Rahima M, Sidi Y et al. Acute coronary events following cisplatin-based chemotherapy. Cancer Invest 1990; 8: 583–6.
38. Cifkova R, Hallen H. Cyclosporin-induced hypertension. J Hypertens 2001; 19: 2283–5.
39. Rodicio JL. Calcium antagonists and renal protection from cyclosporine nephrotoxicity: long-term trial in renal transplantation patients. J Cardiovasc Pharmacol 2000; 35: S7–11.
40. Curtis JJ. Captopril-induced fall in glomerular filtration rate in cyclosporine-treated hypertensive patients. J Am Soc Nephrol 1993; 3: 1570–4.
41. Schmidt A. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serumuric acid levels and potassium homeostasis in hypertensive renal trans-plant recipients treated with CsA. Nephrol Dial Transplant 2001; 16: 1034–7.
42. Grossman EMF. Management of drug-induced and iatrogenic hypertension. In: Hypertension primer. 3rd ed. Dallas, TX: Lippincott Williams& Wilkins, 2003; p. 516–9.
43. Powe DG, Entschladen F. Targeted therapies: Using beta-blockers to inhibit breast cancer progression. Nature Rev Clin Oncol 2011; 8: 511–2.
44. Powe DG, Voss MJ, Zanker KS et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010; 1: 628–38.
45. Gulati G, Heck SL, Hoffman P et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): primary results of a randomized, 2 × 2 factorial, placebo-controlled, double-blind clinical trial. American Heart Association 2015 Scientific Sessions; November 11, 2015; Orlando, FL. Abstract 2015-LBCT-20236-AHA.
46. TITAN (Multidisciplinary Team IntervenTion in CArdio-Oncology). https://clinicaltrials.gov/ct2/show/NCT01621659?term=cardio-oncology&rank=1
47. Chazova I.E., Oshchepkova E.V., Kantorova A.Iu. Komorbidnost' serdechno-sosudistykh i onkologicheskikh zabolevanii: problemy diagnostiki kardiotoksicheskikh effektov khimio- i luchevoi terapii. Terapevt. arkh. 2015; 9 (87): 4–11. [in Russian]
48. Chazova I.E., Oschepkova E.V., Kirillova M.Yu., Sharipova G.Ch. Cardioncology: management of arterial hypertension in patients with cancer on chemotherapy. Systemic Hypertension. 2015; 12 (2): 6–7. [in Russian]
49. Chazova IE, Ovchinnikov AG, Ageev FT. Early diagnostics and prevention of antracycline-induced cardiomyopathy: a role of cardiologist. OnCO Rev 2015; 5 (4 A): 169–76.
2. Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. Распространенность факторов риска сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014; 54: 4–12. / Chazova I.E., Zhernakova Iu.V., Oshchepkova E.V. i dr. Rasprostranennost' faktorov riska serdechno-sosudistykh zabolevanii v rossiiskoi populiatsii bol'nykh arterial'noi gipertoniei. Kardiologiia. 2014; 54: 4–12. [in Russian]
3. Guo X. Association between pre-hypertension and cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Curr Hypertens Rep 2013; 15: 703–16.
4. Hamnvik OP, Choueiri TK, Turchin A et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer 2015; 121 (2): 311–9.
5. Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370:2011–9. Brookes L. National Health and Nutrition Examination Survey (NHANES) data on hypertension. In: American Society of Hypertension 18th Annual Scientific Session. 2003.
6. Caro J, Morales E, Gutierrez E et al. Malignant hypertension in patients treated with vascular endothelial growth factor inhibitors. J Clin Hypertens (Greenwich) 2013; 15: 215–6.
7. Rini BI, Cohen DP, Lu DR et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103: 763–73.
8. Wijermans PW, Lubbert M, Verhoef G et al. An epigenetic approach to the treatment of advanced MDS; the experience withthe DNA demethylating agent 5-aza-2-deoxycytidine (decitabine) in 177 patients. Ann Hematol 2005; 84 (Suppl. 1): 9–17.
9. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 2004; 7: 193–201.
10. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427–34.
11. Oza FM, Cook AD, Pfisterer J et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomized trial. Lancet Oncol 2015; 16: 928–36.
12. Chu TF, Rupnick MA. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011–9.
13. Funakoshi T, Latif A, Galsky MD. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis. J Hum Hypertens 2013; 27: 601–11.
14. Veronese et al. Mechanisms of hypertension associated with BAY43-9006. J Clin Oncol 2006; 24: 1363–9.
15. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009; 6 (8): 465–77.
16. Mourad JJ, Des Guetz G, Debbabi H et al. Blood pressure rise following angiogenesis inhibition bybevacizumab. A crucial role for microcirculation. Ann Oncol 2008; 19: 927–34.
17. Ciuffetti G, Schillaci G, Innocente S et al. Capillary rarefaction and abnormal cardiovascular reactivity in hypertension. J Hypertens 2003; 21: 2297–303.
18. Randall LM, Monk BJ. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol 2010; 117 (3): 497–504.
19. Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY43-9006. J Clin Oncol 2006; 24: 1363–9.
20. Bair SM, Choueiri TK, Moslehi J. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc Med 2013.
21. Диагностика и лечение артериальной гипертонии. Клинические рекомендации. Кардиологический вестн. 2015; 1: 3–30. / Diagnostika i lechenie arterial'noi gipertonii. Klinicheskie rekomendatsii. Kardiologicheskii vestn. 2015; 1: 3–30. [in Russian]
22. Maitland ML, Bakris GL, Black HR et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102: 596–604.
23. Рогоза А.Н., Гориева Ш.Б., Мордвинова Е.В. Возможности тонометров высокого класса точности в обеспечении дистанционного самоконтроля артериального давления. РМЖ. Кардиология. Эндокринология. 2014; 23: 1707–13. / Rogoza A.N., Gorieva Sh.B., Mordvinova E.V. Vozmozhnosti tonometrov vysokogo klassa tochnosti v obespechenii distantsionnogo samokontrolia arterial'nogo davleniia. RMZh. Kardiologiia. Endokrinologiia. 2014; 23: 1707–13. [in Russian]
24. Romano S, Fratini S, Ricevuto E et al. Serial measurements of NT-pro BNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. Br J Cancer 2011; 105: 1663–8.
25. Cardinale D, Sandri MT, Martinoni A et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000; 36: 517–22.
26. Plana JC Et al. Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014; 27: 911–39.
27. Maitland ML, Kasza KE, Karrison TG et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 2009; 15 (19): 6250–7.
28. Jain M, Townsend RR. Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep 2007; 9: 320–8.
29. Kim JJ, Vaziri SA, Rini BI. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 2012; 118 (7): 1946–54.
30. Rini BI, Cohen DP, Lu DR et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103: 763–73.
31. Rini BI, Schiller JH, Fruehauf JP. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011; 17: 3841–9.
32. Copur MS, Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer 2011; 10: 151–6.
33. Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation 2011; 124: 1687–91.
34. Grossman E, Messerli FH. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med 2012; 125: 14–22.
35. Izzedine H, Ederhy S, Goldwasser F et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009; 20: 807–15.
36. Graves SW, Eder JP, Schryber SM et al. Endogenous digoxin-like immunoreactive factor and digitalis-like factor associated with the hypertension of patients receiving multiple alkylating agents as part of autologous bone marrow transplantation. Clin Sci (London) 1989; 77: 501–7.
37. Berliner S, Rahima M, Sidi Y et al. Acute coronary events following cisplatin-based chemotherapy. Cancer Invest 1990; 8: 583–6.
38. Cifkova R, Hallen H. Cyclosporin-induced hypertension. J Hypertens 2001; 19: 2283–5.
39. Rodicio JL. Calcium antagonists and renal protection from cyclosporine nephrotoxicity: long-term trial in renal transplantation patients. J Cardiovasc Pharmacol 2000; 35: S7–11.
40. Curtis JJ. Captopril-induced fall in glomerular filtration rate in cyclosporine-treated hypertensive patients. J Am Soc Nephrol 1993; 3: 1570–4.
41. Schmidt A. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serumuric acid levels and potassium homeostasis in hypertensive renal trans-plant recipients treated with CsA. Nephrol Dial Transplant 2001; 16: 1034–7.
42. Grossman EMF. Management of drug-induced and iatrogenic hypertension. In: Hypertension primer. 3rd ed. Dallas, TX: Lippincott Williams& Wilkins, 2003; p. 516–9.
43. Powe DG, Entschladen F. Targeted therapies: Using beta-blockers to inhibit breast cancer progression. Nature Rev Clin Oncol 2011; 8: 511–2.
44. Powe DG, Voss MJ, Zanker KS et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010; 1: 628–38.
45. Gulati G, Heck SL, Hoffman P et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): primary results of a randomized, 2 × 2 factorial, placebo-controlled, double-blind clinical trial. American Heart Association 2015 Scientific Sessions; November 11, 2015; Orlando, FL. Abstract 2015-LBCT-20236-AHA.
46. TITAN (Multidisciplinary Team IntervenTion in CArdio-Oncology). https://clinicaltrials.gov/ct2/show/NCT01621659?term=cardio-oncology&rank=1
47. Чазова И.Е., Ощепкова Е.В., Канторова А.Ю. Коморбидность сердечно-сосудистых и онкологических заболеваний: проблемы диагностики кардиотоксических эффектов химио- и лучевой терапии. Терапевт. арх. 2015; 9 (87): 4–11. / Chazova I.E., Oshchepkova E.V., Kantorova A.Iu. Komorbidnost' serdechno-sosudistykh i onkologicheskikh zabolevanii: problemy diagnostiki kardiotoksicheskikh effektov khimio- i luchevoi terapii. Terapevt. arkh. 2015; 9 (87): 4–11. [in Russian]
48. Чазова И.Е., Ощепкова Е.В., Кириллова М.Ю., Шарипова Г.Х. Сердечно-сосудистые и онкологические заболевания: поиск решений новых проблем. Системные гипертензии. 2015; 12 (2): 6–7. / Chazova I.E., Oschepkova E.V., Kirillova M.Yu., Sharipova G.Ch. Cardioncology: management of arterial hypertension in patients with cancer on chemotherapy. Systemic Hypertension. 2015; 12 (2): 6–7. [in Russian]
49. Chazova IE, Ovchinnikov AG, Ageev FT. Early diagnostics and prevention of antracycline-induced cardiomyopathy: a role of cardiologist. OnCO Rev 2015; 5 (4 A): 169–76.
________________________________________________
2. Chazova I.E., Zhernakova Iu.V., Oshchepkova E.V. i dr. Rasprostranennost' faktorov riska serdechno-sosudistykh zabolevanii v rossiiskoi populiatsii bol'nykh arterial'noi gipertoniei. Kardiologiia. 2014; 54: 4–12. [in Russian]
3. Guo X. Association between pre-hypertension and cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Curr Hypertens Rep 2013; 15: 703–16.
4. Hamnvik OP, Choueiri TK, Turchin A et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer 2015; 121 (2): 311–9.
5. Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370:2011–9. Brookes L. National Health and Nutrition Examination Survey (NHANES) data on hypertension. In: American Society of Hypertension 18th Annual Scientific Session. 2003.
6. Caro J, Morales E, Gutierrez E et al. Malignant hypertension in patients treated with vascular endothelial growth factor inhibitors. J Clin Hypertens (Greenwich) 2013; 15: 215–6.
7. Rini BI, Cohen DP, Lu DR et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103: 763–73.
8. Wijermans PW, Lubbert M, Verhoef G et al. An epigenetic approach to the treatment of advanced MDS; the experience withthe DNA demethylating agent 5-aza-2-deoxycytidine (decitabine) in 177 patients. Ann Hematol 2005; 84 (Suppl. 1): 9–17.
9. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 2004; 7: 193–201.
10. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427–34.
11. Oza FM, Cook AD, Pfisterer J et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomized trial. Lancet Oncol 2015; 16: 928–36.
12. Chu TF, Rupnick MA. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011–9.
13. Funakoshi T, Latif A, Galsky MD. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis. J Hum Hypertens 2013; 27: 601–11.
14. Veronese et al. Mechanisms of hypertension associated with BAY43-9006. J Clin Oncol 2006; 24: 1363–9.
15. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009; 6 (8): 465–77.
16. Mourad JJ, Des Guetz G, Debbabi H et al. Blood pressure rise following angiogenesis inhibition bybevacizumab. A crucial role for microcirculation. Ann Oncol 2008; 19: 927–34.
17. Ciuffetti G, Schillaci G, Innocente S et al. Capillary rarefaction and abnormal cardiovascular reactivity in hypertension. J Hypertens 2003; 21: 2297–303.
18. Randall LM, Monk BJ. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol 2010; 117 (3): 497–504.
19. Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY43-9006. J Clin Oncol 2006; 24: 1363–9.
20. Bair SM, Choueiri TK, Moslehi J. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc Med 2013.
21. Diagnostika i lechenie arterial'noi gipertonii. Klinicheskie rekomendatsii. Kardiologicheskii vestn. 2015; 1: 3–30. [in Russian]
22. Maitland ML, Bakris GL, Black HR et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102: 596–604.
23. Rogoza A.N., Gorieva Sh.B., Mordvinova E.V. Vozmozhnosti tonometrov vysokogo klassa tochnosti v obespechenii distantsionnogo samokontrolia arterial'nogo davleniia. RMZh. Kardiologiia. Endokrinologiia. 2014; 23: 1707–13. [in Russian]
24. Romano S, Fratini S, Ricevuto E et al. Serial measurements of NT-pro BNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. Br J Cancer 2011; 105: 1663–8.
25. Cardinale D, Sandri MT, Martinoni A et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000; 36: 517–22.
26. Plana JC Et al. Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014; 27: 911–39.
27. Maitland ML, Kasza KE, Karrison TG et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 2009; 15 (19): 6250–7.
28. Jain M, Townsend RR. Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep 2007; 9: 320–8.
29. Kim JJ, Vaziri SA, Rini BI. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 2012; 118 (7): 1946–54.
30. Rini BI, Cohen DP, Lu DR et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103: 763–73.
31. Rini BI, Schiller JH, Fruehauf JP. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011; 17: 3841–9.
32. Copur MS, Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer 2011; 10: 151–6.
33. Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation 2011; 124: 1687–91.
34. Grossman E, Messerli FH. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med 2012; 125: 14–22.
35. Izzedine H, Ederhy S, Goldwasser F et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009; 20: 807–15.
36. Graves SW, Eder JP, Schryber SM et al. Endogenous digoxin-like immunoreactive factor and digitalis-like factor associated with the hypertension of patients receiving multiple alkylating agents as part of autologous bone marrow transplantation. Clin Sci (London) 1989; 77: 501–7.
37. Berliner S, Rahima M, Sidi Y et al. Acute coronary events following cisplatin-based chemotherapy. Cancer Invest 1990; 8: 583–6.
38. Cifkova R, Hallen H. Cyclosporin-induced hypertension. J Hypertens 2001; 19: 2283–5.
39. Rodicio JL. Calcium antagonists and renal protection from cyclosporine nephrotoxicity: long-term trial in renal transplantation patients. J Cardiovasc Pharmacol 2000; 35: S7–11.
40. Curtis JJ. Captopril-induced fall in glomerular filtration rate in cyclosporine-treated hypertensive patients. J Am Soc Nephrol 1993; 3: 1570–4.
41. Schmidt A. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serumuric acid levels and potassium homeostasis in hypertensive renal trans-plant recipients treated with CsA. Nephrol Dial Transplant 2001; 16: 1034–7.
42. Grossman EMF. Management of drug-induced and iatrogenic hypertension. In: Hypertension primer. 3rd ed. Dallas, TX: Lippincott Williams& Wilkins, 2003; p. 516–9.
43. Powe DG, Entschladen F. Targeted therapies: Using beta-blockers to inhibit breast cancer progression. Nature Rev Clin Oncol 2011; 8: 511–2.
44. Powe DG, Voss MJ, Zanker KS et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010; 1: 628–38.
45. Gulati G, Heck SL, Hoffman P et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): primary results of a randomized, 2 × 2 factorial, placebo-controlled, double-blind clinical trial. American Heart Association 2015 Scientific Sessions; November 11, 2015; Orlando, FL. Abstract 2015-LBCT-20236-AHA.
46. TITAN (Multidisciplinary Team IntervenTion in CArdio-Oncology). https://clinicaltrials.gov/ct2/show/NCT01621659?term=cardio-oncology&rank=1
47. Chazova I.E., Oshchepkova E.V., Kantorova A.Iu. Komorbidnost' serdechno-sosudistykh i onkologicheskikh zabolevanii: problemy diagnostiki kardiotoksicheskikh effektov khimio- i luchevoi terapii. Terapevt. arkh. 2015; 9 (87): 4–11. [in Russian]
48. Chazova I.E., Oschepkova E.V., Kirillova M.Yu., Sharipova G.Ch. Cardioncology: management of arterial hypertension in patients with cancer on chemotherapy. Systemic Hypertension. 2015; 12 (2): 6–7. [in Russian]
49. Chazova IE, Ovchinnikov AG, Ageev FT. Early diagnostics and prevention of antracycline-induced cardiomyopathy: a role of cardiologist. OnCO Rev 2015; 5 (4 A): 169–76.
Авторы
И.Е.Чазова1, Е.В.Ощепкова1, М.Ю.Кириллова*1, М.Б.Стенина2
1 ФГБУ Российский кардиологический научно-производственный комплекс Минздрава России. 121552, Россия, Москва, ул. 3-я Черепковская, д. 15а;
2 ФГБУ Российский онкологический научный центр им. Н.Н.Блохина Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23
*register.ihd.rus@gmail.com
1 ФГБУ Российский кардиологический научно-производственный комплекс Минздрава России. 121552, Россия, Москва, ул. 3-я Черепковская, д. 15а;
2 ФГБУ Российский онкологический научный центр им. Н.Н.Блохина Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23
*register.ihd.rus@gmail.com
________________________________________________
1 Russian Cardiological Scientific-Industrial Complex of the Ministry of Health of the Russian Federation. 121552, Russian Federation, Moscow, ul. 3-ia Cherepkovskaia, d. 15a;
2 N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
*register.ihd.rus@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.